These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20444543)

  • 1. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
    Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
    Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Cadherin and Tie2 positive CD34⁺CD38⁻CD123⁺ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice.
    Qiu S; Jia Y; Xing H; Yu T; Yu J; Yu P; Tang K; Tian Z; Wang H; Mi Y; Rao Q; Wang M; Wang J
    Leuk Res; 2014 May; 38(5):632-7. PubMed ID: 24703771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia.
    Hwang K; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
    Ann Hematol; 2012 Oct; 91(10):1541-6. PubMed ID: 22669506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity.
    She M; Niu X; Chen X; Li J; Zhou M; He Y; Le Y; Guo K
    Cancer Lett; 2012 May; 318(2):173-9. PubMed ID: 22198207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
    Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
    Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
    van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells.
    Georgantas RW; Tanadve V; Malehorn M; Heimfeld S; Chen C; Carr L; Martinez-Murillo F; Riggins G; Kowalski J; Civin CI
    Cancer Res; 2004 Jul; 64(13):4434-41. PubMed ID: 15231652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
    Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
    Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Cadherin Aided in Maintaining the Characteristics of Leukemic Stem Cells.
    Zhi L; Gao Y; Yu C; Zhang Y; Zhang B; Yang J; Yao Z
    Anat Rec (Hoboken); 2016 Jul; 299(7):990-8. PubMed ID: 27064800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
    Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
    Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.